GlassScriptPhysician profile
Scott R Goodwin
NPI 1831310226
$856.55
in general payments reported to CMS, 2019-2025
13 companies · $29.37 in 2025
The $29.37 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $103 · 2021: $126 · 2022: $242 · 2023: $92.26 · 2025: $29.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $333.68 | 2019-2025 | Diamondback Coronary, Freestyle Libre 2 |
| Medtronic, INC. | $178.91 | 2022 | |
| Novo Nordisk INC | $80.31 | 2019-2023 | Rybelsus, Tresiba, Ozempic |
| Astrazeneca Pharmaceuticals LP | $71.77 | 2019-2020 | |
| Lilly USA, LLC | $36.39 | 2019-2022 | |
| Abbvie INC. | $28.82 | 2021-2023 | |
| Medtronic Minimed, INC. | $25.12 | 2020 | |
| Insulet Corporation | $18.84 | 2019 | |
| Dexcom, INC. | $18.66 | 2023 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $17.57 | 2020 | |
| Tandem Diabetes Care, INC. | $16.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.06 | 2019 | |
| Janssen Biotech, INC. | $14.18 | 2023 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.